News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Nomination Committee for the 2014 Annual General Meeting in PledPharma AB

November 18, 2013

PledPharma AB
Company Announcement

Nomination Committee for the 2014 Annual General Meeting in PledPharma AB

Stockholm, 2013-11-18 14:03 CET (GLOBE NEWSWIRE) -- 

In consultation with the largest shareholders, the Chairman of PledPharma has
established a Nomination Committee for the 2014 Annual General Meeting that is
to be held on April 8. The committee consists of Staffan Persson, Peter
Lindell, Gunnar Lindberg and Håkan Åström (Chairman of PledPharma). Staffan
Persson will act as convener for the Nomination Committee. 

The Committee's task is to present proposals regarding Chairman and other
members of the board and fees and other remuneration to the Board´s members.
The Nominating Committee shall also submit proposals for appointment and
remuneration of auditors. Further, the Committee shall submit proposals to the
process to appoint the Nomination Committee for the AGM in 2015. 

Shareholders who wish to submit proposals to the Nomination Committee can do so
by e-mail: 

For more information please contact:

Håkan Åström, Chairman

Phone: +46 703 747 213

Jacques Näsström, CEO

Phone: +46 737 130 979

About PledPharma
PledPharma is a Swedish specialty pharma company that develops PledOx® for
prevention of severe chemotherapy-induced side effects in cancer patients. Due
to these side effects optimal treatment cannot be carried out. The current
market for supportive cancer care is some SEK 72 billion. PledOx protects
normal cells against oxidative stress. It belongs to a group of compounds named
lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese
SuperOxide Distmutase (MnSOD) – the most important endogenous cellular
protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10